ABCL
Price
$8.12
Change
+$0.74 (+10.03%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
2.48B
34 days until earnings call
Intraday BUY SELL Signals
ADPT
Price
$21.18
Change
+$0.22 (+1.05%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
3.39B
33 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs ADPT

ABCL vs ADPT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABCL vs. ADPT commentary
Jul 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Buy and ADPT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2026
Stock price -- (ABCL: $7.38 vs. ADPT: $20.96)
Brand notoriety: ABCL: Not notable vs. ADPT: Notable
ABCL represents the Biotechnology, while ADPT is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ABCL: 168% vs. ADPT: 211%
Market capitalization -- ABCL: $2.48B vs. ADPT: $3.39B
ABCL [@Biotechnology] is valued at $2.48B. ADPT’s [@Medical Specialties] market capitalization is $3.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $134.02B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B. The average market capitalization across the [@Medical Specialties] industry is $17.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileADPT’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • ADPT’s FA Score: 0 green, 5 red.
According to our system of comparison, ADPT is a better buy in the long-term than ABCL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 5 TA indicator(s) are bullish while ADPT’s TA Score has 7 bullish TA indicator(s).

  • ABCL’s TA Score: 5 bullish, 4 bearish.
  • ADPT’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, ADPT is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а +10.81% price change this week, while ADPT (@Medical Specialties) price change was +3.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.30%. For the same industry, the average monthly price growth was +5.93%, and the average quarterly price growth was +1921.84%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.03%. For the same industry, the average monthly price growth was +9.32%, and the average quarterly price growth was +10.59%.

Reported Earning Dates

ABCL is expected to report earnings on Aug 06, 2026.

ADPT is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Biotechnology (+2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (+3.03% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADPT($3.39B) has a higher market cap than ABCL($2.48B). ABCL YTD gains are higher at: 115.789 vs. ADPT (29.064). ADPT has higher annual earnings (EBITDA): -20.94M vs. ABCL (-167.02M). ABCL has more cash in the bank: 505M vs. ADPT (218M). ADPT has less debt than ABCL: ADPT (77.6M) vs ABCL (140M). ADPT has higher revenues than ABCL: ADPT (295M) vs ABCL (79.2M).
ABCLADPTABCL / ADPT
Capitalization2.48B3.39B73%
EBITDA-167.02M-20.94M798%
Gain YTD115.78929.064398%
P/E RatioN/AN/A-
Revenue79.2M295M27%
Total Cash505M218M232%
Total Debt140M77.6M180%
FUNDAMENTALS RATINGS
ADPT: Fundamental Ratings
ADPT
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLADPT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 24 days ago
82%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signal:
Gain/Loss:
ADPT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KRYP17.500.93
+5.59%
Proshares Coindesk 20 Crypto ETF
XPH67.161.84
+2.82%
State Street® SPDR® S&P® PhrmctlsETF
PBNV30.96N/A
+0.01%
PGIM S&P 500 Buffer 20 ETF - Nov
XOCT39.51-0.02
-0.06%
FT Vest US Eq Enh & Mod Buf ETF-Oct
FRDM68.44-1.34
-1.92%
Freedom 100 Emerging Markets ETF

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
N/A
RXRX - ABCL
60%
Loosely correlated
N/A
PRME - ABCL
57%
Loosely correlated
N/A
CRSP - ABCL
56%
Loosely correlated
N/A
VCYT - ABCL
56%
Loosely correlated
N/A
ABSI - ABCL
54%
Loosely correlated
N/A
More

ADPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADPT has been loosely correlated with AXON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADPT jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADPT
1D Price
Change %
ADPT100%
N/A
AXON - ADPT
56%
Loosely correlated
N/A
VCYT - ADPT
50%
Loosely correlated
N/A
ARRY - ADPT
50%
Loosely correlated
N/A
PSNL - ADPT
49%
Loosely correlated
N/A
NTRA - ADPT
46%
Loosely correlated
N/A
More